ClinicalTrials.gg
Not yet recruitingNCT07942259HA35-CHEWUpdated Nov 17, 2026

35-kDa Hyaluronan Fragment (HA35) Chewable Tablets for Gingival Inflammation, Oral Pain and Pharyngeal Discomfort

An interventional study of 35-kDa Hyaluronan Fragment (HA35) Chewable Tablet in Gingival Inflammation, Gingival Recession and Post-Dental-Procedure Oral Pain, sponsored by Nakhia Impex LLC. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Nakhia Impex LLC · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Gingivitis with a site in China — 7 open to participants now, 7 under way, 2 of them phase 3. Gingivitis · China.

Planned enrollment
14th of 15
30 · median 98
Started
2026
with 5 others
No phase
8 of 18
3 open now
Registered
18th of 18
by date
Lead sponsor
1 of 18
Nakhia Impex LLC

Among the 18 studies in Gingivitis with a site in China, this one is the 14th largest by planned enrollment of the 15 interventional ones that give a count, is one of 6 that started in 2026, is one of 8 with no phase, and was the 18th registered.

Gingivitis

631 studies on the registry are indexed under Gingivitis; 107 are open to participants now.

Browse Gingivitis studies →

Open to participants now

7 of the 18 studies in Gingivitis with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 53 Gingivitis studies recruiting now, 15 (28%) set no upper age limit and 36 (68%) stop at 75 or younger; 11 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Gingivitis with a site in China, or all of them as a file.
02

Study summary

To explore efficacy and safety of 35-kDa hyaluronan fragment (HA35) chewable tablets for relief of tooth-gingival pain, periodontal gingival inflammation, mild gingival recession, and pharyngeal itching-pain. Participants chew six tablets per dose, three times daily for 28 consecutive days. Assess subjective oral-pharyngeal symptoms, gingival inflammation, estimated gingival regrowth and safety events.

Read the detailed description

This is prospective, single-arm, open-label pilot clinical study. Eligible adult participants with periodontal condition, mild gingival recession and oral-gingival pain or pharyngeal discomfort receive HA35 chewable tablets. Each tablet weighs 600 mg containing 300 mg 35-kDa hyaluronan fragment. Subjects chew six tablets each administration (3 tablets on each molar side), three times daily for total 18 tablets/day (5.4 g HA35/day), for 28 consecutive days. Tablets dissolve by saliva in oral cavity after chewing. Evaluations are performed at baseline; 3 minutes post-first dose; 30 minutes post-first dose; Day 1, Day 7, Day 21, Day 28. Investigator assess gingival redness/swelling, exposed root length for estimated gingival regrowth. Subject self-report pain, itch-pain of throat. Exploratory facial-tissue related assessments are performed at Day 28. Adverse events are monitored throughout whole 28-day study period. Target enrollment: 30 adult participants.

03

Conditions studied

  • Gingival Inflammation
  • Gingival Recession
  • Post-Dental-Procedure Oral Pain
  • Pharyngeal Pain
  • Pharyngeal Pruritus

Keywords

  • periodontal inflammation
  • gingival pain
  • post-dental-treatment pain
  • gingival regrowth
  • pharyngeal itch
  • HA35
  • hyaluronan fragment
  • chewable tablet
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years old, male or female adult.
  2. Clinical findings of periodontal disease with mild gingival recession; with at least one of following: chronic gingival/tooth-root pain; pain after dental procedure (restoration, scaling, extraction, transplantation etc.); subjective pharyngeal itching or pharyngeal pain.
  3. Able to independently complete NRS scale self-assessment.
  4. Able to follow full 28-days three-times-daily chewable-tablet protocol.
  5. Voluntarily sign written informed-consent document.

Exclusion criteria

Exclusion Criteria:

  1. Severe periodontal disease requiring immediate surgical intervention; active oral ulcer, oral malignant lesion.
  2. Pregnant or lactating women.
  3. Known / allergy to hyaluronan / sodium hyaluronate or tablet .
  4. Severe gastrointestinal diseases.
  5. Simultaneous participation in other oral-pharyngeal-related clinical trials.
  6. Psychiatric disorders that compromise study compliance.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    HA35 Chewable Tablets

    Other: 35-kDa Hyaluronan Fragment (HA35) Chewable Tablet

Interventions

  • Other35-kDa Hyaluronan Fragment (HA35) Chewable Tablet

    Intervention description: Each tablet 600 mg containing 300 mg HA35. Chew six tablets per dose (3 each side molars), three times daily, total 18 tablets/day (5.4 g HA35/day), 28 consecutive days. Tablets dissolve in saliva after chewing.

06

What researchers measure

Primary outcomes

  1. Primary Outcome Measures

    Participant-reported 0-10 numerical rating scale for tooth and gingival pain; 0=no pain,10=worst imaginable pain

    Time frame: Baseline, 3 minutes after first administration, Day-1, Day-7, Day-28

  2. Pharyngeal Itching-Pain NRS Score

    Participant-reported 0-10 NRS for throat itching and pain;0=no symptom, 10=worst imaginable itch-pain

    Time frame: Baseline,30 minutes after first administration, Day-1, Day-7, Day-28

  3. Gingival Inflammatory Redness-Swelling NRS Score

    Investigator-rated composite 0-10 score of gingival redness and swelling;0=no inflammation;10=severe gingival redness and swelling

    Time frame: Baseline, Day-1, Day-7, Day-21, Day-28

Secondary outcomes

  1. Estimated Gingival Regrowth Length (mm)

    Investigator measurement of exposed tooth-root length using 1-mm precision ruler; calculate estimated gingival regrowth from baseline

    Time frame: Baseline, Day-21, Day-28

  2. Exploratory Facial-tissue Reduction Score

    Investigator visual-tactile 0-10 rating scale (exploratory only): reduction of facial roundness, forehead-skin thickness, eyelid thickness, double-chin prominence;0=no reduction;10=maximum reduction. Exploratory endpoint only

    Time frame: Baseline, Day-28

  3. Participant Overall Satisfaction Score

    Participant self-reported overall satisfaction 0-10 scale for oral-pharyngeal improvement. 0=most dissatisfied, 10=most satisfied

    Time frame: Day-28 end-of-treatment

  4. Adverse Event Incidence

    Incidence of product-related adverse events including oral mucosal irritation, hypersensitivity, gastrointestinal discomfort, throat irritation

    Time frame: Entire 28-day study period

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jan 2027, 0 months later.

Of 53 industry-sponsored interventional studies with no phase under Gingivitis, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 5. This study's planned 0 months is below that.

Counting every sponsor, half of 257 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Dec 15, 2026
Primary completionEst.
Jan 12, 2027
CompletionEst.
Jan 19, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942259
Lead sponsor
Nakhia Impex LLC
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 15, 2026 (estimated)
Primary completion
Jan 12, 2027 (estimated)
Completion
Jan 19, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Mizhou Hui
Contact
mizhou.hui@alumni.utoronto.ca
13484005199

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion